Vail D, et al. - In the U.S. population, researchers assessed the effect of lipid-lowering medications on diabetic retinopathy and diabetic complications requiring intervention. For this retrospective cohort analysis, they involved 269,782 subjects diagnosed with type 2 diabetes mellitus between 2008 and 2015. The authors discover coherent proof that patients on lipid-lowering drugs are less likely to create non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, or diabetic macular edema, and modest proof that these patients are less likely to receive anti-VEGF injections, laser therapies, or vitrectomy. The research validates the findings of studies in relatively homogeneous populations using claim databases in East Asia to estimate an association between statin usage and retinopathy, replicating them in a large commercial claims database in a U.S. context.